Your first 90 days
Your first 90 days on Takhzyro for hereditary angioedema (HAE)
What happens before the first fill, the days that matter, the label's rules and who to call, from the label, the drugmaker's own program and one insurer's written rules.
Takhzyro has no safety program forms, no required blood tests and no dose build-up. The first shot waits on a Start Form, an insurance approval, a specialty pharmacy delivery and injection training. After that comes a routine of one refrigerated syringe every 2 weeks for most people. This page lays out those weeks from the FDA label, Takeda's own Takhzyro pages and one insurer's written rules.
What has to happen before the first bottle ships
Takhzyro has no REMS, so the first shot waits on the Start Form, a prior authorization, a pharmacy delivery and injection training. These are the 6 things in the way, in order.
The Start Form, signed twice
Takeda says the Takhzyro Start Form acts as the prescription.
- The prescriber signs it, and you sign the patient authorization so Takeda Patient Support can check your benefits without delay.Enrollment steps
A call from Takeda Patient Support
If you agreed to Takeda Patient Support on the form, a support specialist calls within 2 to 4 days.
- Takeda suggests saving 1-866-888-0660 in your phone so spam blockers do not stop the call.Enrollment steps
The insurance approval
Takeda says a prior authorization will generally be needed before treatment begins.
- Plans such as Cigna ask for lab results showing HAE type I or type II and an allergist, immunologist or HAE specialist.Cigna policy
Free medicine while benefits are checked
The Quick Start Program can send up to 2 months of Takhzyro at no cost to people with commercial insurance while full benefits are verified.
- People on Medicare or Medicaid are not eligible for it.Enrollment steps
Injection training
The label says a healthcare provider should train you or your caregiver before the first self-injection.
- Takeda Patient Support can arrange in-home training from a specially trained nurse.Takeda Patient Support
A medicine list for your care team
The Patient Information asks you to tell your provider about every medicine, vitamin and herbal supplement.
- The label says no dedicated drug interaction studies have been done.FDA label
The days that matter
Counted from the first shot, with doses every 2 weeks, the first refill and the point where blood levels level off. Type your first-dose date and the tiles become real dates you can add to your calendar.
The tiles below count days from a first dose. Enter the date of yours, or the date you expect, and each tile becomes a real date on your calendar.
The date stays on your device. It is not sent to Trial Friend or anyone else. The calendar file works with Apple, Google and Outlook calendars.Start Form, then the benefits check
The office sends the Start Form, and for commercial insurance often the Quick Start form, by fax or online.
- Takeda Patient Support then begins the benefits investigation.
- No source sets how long approval takes.
The support specialist calls
Takeda says a support specialist calls within 2 to 4 days if you agreed to the program.
- The call can come from a number you do not know.
Delivery and injection training
A specialty pharmacy ships the syringes, which go straight into the refrigerator in their cartons.
- A nurse or the clinic shows you or your caregiver how to give the shot.
First dose
One 300mg prefilled syringe from age 12, into the belly, thigh or upper arm.
- Take the carton out of the refrigerator 15 minutes before the shot so it reaches room temperature.
Second dose, then every 2 weeks
On the every-2-week schedule, doses fall on days 15, 29, 43, 57, 71 and 85.
- Each new shot goes at least 1 inch from the last spot used.
Second dose, number 2
First refill, then about every 4 weeks
Each carton holds one syringe, so a 4-week supply on the every-2-week schedule is 2 cartons.
- A first fill through the Quick Start Program can cover up to 2 months instead.
Second dose, number 3
Second dose, number 4
First refill, number 2
Levels level off
The label says Takhzyro takes about 70 days to reach a steady level in the blood.
- Its half-life is about 2 weeks.
Second dose, number 5
Second dose, number 6
First refill, number 3
Three months in
The label considers every-4-week dosing only after more than 6 months of good control, so the every-2-week schedule usually continues here.
- The allergist decides any change.
The label, revision by revision
The FDA lists which sections changed in each revision of a label. These are the revisions the current Takhzyro label records, dated by the FDA, with a plain note on what each one meant for a patient. Older references and handouts can lag these by months.
Current label dated September 18, 2026, read from the FDA's label database today. FDA label
- August 2026
The FDA approved removing the single-dose vial from the label, leaving the 150mg and 300mg prefilled syringes. The same change added hives at the injection site to side effects reported since approval.FDA letter
- February 2023
The FDA widened approval to children 2 to under 12. It added 150mg every 2 weeks for ages 6 to 11 and 150mg every 4 weeks for ages 2 to 5. A 150mg prefilled syringe came with it.FDA letter
- February 2022
This label lists a ready-to-use 300mg prefilled syringe alongside the vial, with syringe instructions in the dosing section.FDA label, Feb 2022
- November 2018
This was a formatting change only. The line on how to report side effects moved within the label's highlights.FDA letter
- August 2018
The FDA first approved Takhzyro on August 23rd to prevent HAE attacks in people 12 and older.FDA letter
How the label says to take it
The parts of the prescribing information and the patient leaflet that come up in the first 3 months, in plain words.
- The dose by age
From age 12, 300mg every 2 weeks, with every 4 weeks considered after more than 6 months of good control.
- Ages 6 to 11 get 150mg every 2 weeks, and ages 2 to 5 get 150mg every 4 weeks.FDA label
- Who gives the shot
From age 12, the patient or a caregiver may inject after training.
- For children 2 to 11, the label says a healthcare provider or caregiver gives the dose, and self-injection is not recommended.FDA label
- Where the shot goes
Use the belly, the thighs or the upper arms, at least 2 inches from scars or the belly button.
- The 300mg instructions say the upper arm is only for a provider or caregiver.FDA label
- If a dose is missed
The US label and Patient Information do not give a missed-dose rule.
- Ask the prescriber what to do, and write the answer down before the first shot.FDA label
- It prevents attacks, it does not treat one
The label approves Takhzyro only to prevent HAE attacks.
- In the main trial, everyone could still use rescue medicine for breakthrough attacks.
- The allergist decides which on-demand medicine you keep on hand.FDA label
- Clotting tests can read high
Takhzyro can lengthen the aPTT blood clotting test because of how the test works.
- In the main trial none of these changes came with abnormal bleeding.
- Tell the lab and any doctor ordering it.FDA label
- Storage
Keep syringes in the refrigerator at 36°F to 46°F (2°C to 8°C), in the carton to block light.
- Do not freeze or shake them.
- The instructions say to throw away a syringe kept out of the refrigerator.FDA label
- Warming before the shot
Take the carton out 15 minutes before injecting.
- The instructions say not to warm the syringe with a microwave or hot water, and not to use it if the carton seal is broken.FDA label
- Needles and sharps
Put each used syringe in a sharps container right away, and never reuse it.
- The instructions describe a heavy plastic container with a tight lid if you do not have an FDA-cleared one.FDA label
- Pregnancy and breastfeeding
There are no data on Takhzyro in pregnant women.
- The label says antibodies like it cross the placenta mostly in the third trimester.
- It is not known whether it passes into breast milk.FDA label
What the label says to act on
The symptoms the label singles out, and what it tells patients and prescribers to do about each. If any of these happen, the label's instruction is the one to follow, with your care team.
Signs of an allergic reaction
Wheezing, trouble breathing, chest tightness, a fast heartbeat, feeling faint, a rash or hives.
- The Patient Information says to call your provider or get emergency help right away.
- In the main trial, allergic reactions occurred in 1% on Takhzyro against 0% on placebo.FDA label
Reactions where the shot went in
Pain, redness and bruising at the injection site were the most common side effect.
- They occurred in 52% of people on Takhzyro against 34% on placebo.
- Hives at the injection site have been reported since approval.FDA label
Other common side effects
Upper respiratory infections, headache, rash, dizziness, diarrhea and muscle aches were the other common side effects.
- The Patient Information says to tell your provider about any side effect that bothers you or does not go away.FDA label
Attacks that keep coming
In the main trial, 44% on the every-2-week dose had no attacks over 26 weeks, against 2% on placebo.
- The attack rate on that dose was 87% lower than on placebo, so breakthrough attacks can still happen.
- The allergist decides what they mean for the plan.FDA label
Why the pharmacy or the insurer says no, and what fixes it
Most first-fill delays are one of these. Knowing which one tells you who to call.
- Prior authorization pending or deniedCigna asks for a functional C1-INH level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist. The policy marks both lab results as required documents, so the office sends both reports.Cigna policy
- An appeal after a denialTakeda's prescriber site offers appeal templates, including a statement of medical necessity and a formulary exception letter. Takeda Patient Support can answer the office's questions about denials and appeals. The office files the appeal.HCP enrollment page
- HAE with normal C1-INHCigna's policy says HAE with normal C1-INH, also called type III, does not meet its diagnosis requirement. The Takhzyro label describes its main trial in type I and type II HAE. The allergist can explain the diagnosis to the plan.Cigna policy
- Another preventive medicine at the same timeCigna lists Takhzyro used with other preventive HAE medicines, such as Cinryze, Haegarda or Orladeyo, as not medically necessary. Medicines that treat an attack, or prevent one around a procedure, are allowed.Cigna policy
- A dose the plan will not coverCigna approves 300mg no more often than every 2 weeks from age 12, and 150mg on the label's schedules for children. Other doses go to case-by-case review by a Cigna clinician.Cigna policy
- A copay you cannot payWith commercial insurance, the Takeda co-pay program can cover up to 100% of out-of-pocket co-pays, up to a yearly maximum. Medicare, Medicaid, TRICARE, VA and other government plans are excluded. Takeda says it may connect people who cannot afford treatment to other programs.Takeda Patient Support
- The plan uses a co-pay maximizerTakeda says it may lower or end co-pay help for people in a plan with a co-pay maximizer program. Its terms ask you to tell the program at 1-866-888-0660 if you learn your plan uses one.Takeda Patient Support
Cigna prior authorization policy, January 1, 2026
- HAE type I or type II, with a functional C1-INH protein level under 50% of normal at baseline, with lab documentation
- A serum C4 level below normal at baseline, with lab documentation
- HAE with normal C1-INH, also called type III, does not meet the diagnosis requirement
- Prescribed by or in consultation with an allergist, immunologist or a physician who specializes in HAE
- From age 12, 300mg no more often than every 2 weeks; at ages 6 to 11, 150mg every 2 weeks; under 6, up to 150mg every 4 weeks
- Not used together with another preventive HAE medicine such as Cinryze, Haegarda or Orladeyo
Approval length. Approved a year at a time. Renewal asks for HAE type I or II and a favorable response, such as fewer, milder or shorter attacks.
This version took effect January 1, 2026. It still cites the February 2023 label, which predates the August 2026 label that removed the vial and added injection site hives. Neither change touches its criteria. Its 2026 update dropped a genetic-test route to diagnosis. Other plans set their own criteria. It is here as an example, not as a rule. Cigna policy
Who to call, and what they can do
The drugmaker's program handles most of the first-fill problems above. Charity funds and foundation help are on the help paying page.
- A support specialist who reviews your coverage and explains financial options
- The Takeda Patient Support Co-Pay Assistance Program for commercial insurance, including Marketplace plans, covering up to 100% of out-of-pocket co-pays up to a yearly maximum
- No co-pay help for Medicare, Medicare Advantage, Medicaid, TRICARE, VA or other federal or state plans
- Work with your specialty pharmacy to get Takhzyro to you
- In-home injection training from a specially trained nurse
- The Quick Start Program, up to 2 months of Takhzyro at no cost for commercially insured patients while benefits are verified Enrollment steps
- Help over the phone in other languages through a translation service
Details as the drugmaker publishes them. Takeda Patient Support
Five questions for the pharmacist or the support line
- How many syringes come in each shipment, and when should I expect the next one?
- What do I do if a shipment arrives warm or sits outside the refrigerator?
- Is my syringe the 300mg one or the 150mg one, and does the carton match my prescription?
- Where can I get a sharps container for used syringes?
- Which on-demand HAE medicine do I keep at home, and is that prescription current?
Questions people ask in the first weeks
How often is Takhzyro given?
From age 12, the label dose is 300mg every 2 weeks. Every 4 weeks may be considered once someone is well controlled, such as attack free, for more than 6 months. Children 6 to 11 get 150mg every 2 weeks, and children 2 to 5 get 150mg every 4 weeks.
Can I give Takhzyro myself?
Yes, from age 12 the label lets the patient or a caregiver inject after training by a healthcare provider. For children 2 to 11, a provider or caregiver gives the shot. Takeda Patient Support can arrange in-home injection training.
Does Takhzyro treat an HAE attack?
No, the label approves it only to prevent attacks. In the main trial, everyone could use rescue medicine for breakthrough attacks. The allergist or immunologist decides which on-demand medicine you keep on hand.
Do I need blood tests on Takhzyro?
No, the label sets no routine blood tests. In the main trial, a few people had short-lived rises in liver enzymes without symptoms. Takhzyro can also raise the aPTT clotting test, so tell the lab.
How do I store Takhzyro?
In the refrigerator at 36°F to 46°F (2°C to 8°C), in the original carton, never frozen or shaken. The instructions say to throw away a syringe kept out of the refrigerator. Take it out 15 minutes before the shot.
Does Medicare work with the Takhzyro co-pay program?
No, the Takeda co-pay program excludes Medicare, Medicare Advantage, Medicaid, TRICARE, VA and other government plans. The Quick Start Program also excludes Medicare and Medicaid. Takeda says it may connect people who cannot afford treatment with other programs.
Free email alert
Hear when the Takhzyro label changes
One email the day the FDA revises the Takhzyro label, with what changed in plain words. No trial alerts, no newsletter.
Label changes for Takhzyro only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Want the whole condition instead? Follow Hereditary angioedema (HAE) for new trials, FDA decisions and label changes for every treatment.
Sources
- DailyMed - TAKHZYRO- lanadelumab-flyo injection, solution (prescribing information revised 8/2026, Patient Information revised 8/2026, Instructions for Use approved 8/2026), Takeda Pharmaceuticals America, Inc., via DailyMed, September 18, 2026.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, November 10, 2026.
- Personalized Product Support | TAKHZYRO® (lanadelumab-flyo), Takeda, November 10, 2026.
- Follow these 4 simple steps (TAKHZYRO patient enrollment by fax), Takeda, November 10, 2026.
- Patient Enrollment | TAKHZYRO® (lanadelumab-flyo), Takeda, November 10, 2026.
- Patient Support | TAKHZYRO® (lanadelumab-flyo), Takeda, November 10, 2026.
- Hereditary Angioedema, Takhzyro, Drug Coverage Policy IP0334, Cigna, January 1, 2026.
- BLA 761090/S-020 supplement approval letter, injection site urticaria and removal of the single-dose vial, FDA, August 20, 2026.
- BLA 761090/S-010 supplement approval letter, pediatric patients 2 to less than 12 years, FDA, February 3, 2023.
- TAKHZYRO prescribing information, revised 02/2022 (BLA 761090/S-003), FDA, February 8, 2022.
- BLA 761090/S-001 supplement approval letter, Highlights formatting change, FDA, November 16, 2018.
- BLA 761090 approval letter, TAKHZYRO (lanadelumab-flyo), FDA, August 23, 2018.
This page explains what the FDA label, the drugmaker's support program and an insurer policy say. It is not medical advice and does not tell anyone to start, stop or change a medicine. Dosing, test timing and restarts after a gap are decisions for the prescribing allergist or immunologist. Found an error? Use the report link in the footer and it will be checked against the source.